(Q54400499)

English

A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. (English)

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Lisa L. von Moltke

6

object named as

Lisa L von Moltke

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

author name string

Meng Zhang

1

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

Christine R Xu

2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

Elias Shamiyeh

3

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

Feng Liu

4

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

Jian Y Yin

5

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

William B Smith

7

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

publication date

16 November 2013

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

54

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

4

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

415-421

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

The history of myeloproliferative disorders: before and after Dameshek

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

Improving survival trends in primary myelofibrosis: an international study.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

The role of cytokines in the initiation and progression of myelofibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.218

21 January 2018

Identifiers

10.1002/JCPH.218

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24165976

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54400499&oldid=2143972281"